Effect of aldosterone breakthrough on albuminuria during treatment with a direct renin inhibitor and combined effect with a mineralocorticoid receptor antagonist

Hypertension Research

Volumn 36, Issue 10, 2013, Pages 879-884

  Sato, Atsuhisa ^a   Fukuda, Seiichi ^a  

^a International University of Health and Welfare Mita Hospital   (Japan)

Author keywords

Aldosterone; Aldosterone breakthrough; Direct renin inhibitor; Mineralocorticoid receptor antagonist; Urinary albumin excretion

Indexed keywords

ALBUMIN; ALDOSTERONE; ALISKIREN; AMLODIPINE; EPLERENONE;

AGED; ALBUMINURIA; ALDOSTERONE BLOOD LEVEL; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; DEPRESSED BLOOD PRESSURE; DRUG DOSE INCREASE; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; HYPERTENSION; LONG TERM CARE; MALE; MORNING DOSAGE; PLASMA RENIN ACTIVITY;

AGED; ALBUMINURIA; ALDOSTERONE; AMIDES; BLOOD PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; FUMARATES; HUMANS; HYPERTENSION; INCIDENCE; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MINERALOCORTICOID RECEPTOR ANTAGONISTS; RENIN; RENIN-ANGIOTENSIN SYSTEM; SPIRONOLACTONE; TIME FACTORS;

EID: 84885115254     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2013.74     Document Type: Article

References (44)

1. Dzau VJ. Theodore Cooper Lecture. Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension 2001; 37: 1047-1052.
2. The Japanese Society of Hypertension Committee. The Japanese Society of Hypertension Committee for Guidelines for the Management of Hypertension. Hypertens Res 2009; 32: 1-107.
3. Zaman MA, Oparil S, Calhoun DA. Drugs targeting the renin-angiotensin- aldosterone system. Nat Rev Drug Discov 2002; 1: 621-636.
4. Stanton A, Jensen C, Nussberger J, Obrien E. Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension 2003; 42: 1137-1143.
5. Gradman AH, Schmieder RE, Lins RL, Nussberger J, Chiang Y, Bedigian MP. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation 2005; 111: 1012-1028.
6. Krone W, Hanefeld M, Meyer HF, Jung T, Bartlett M, Yeh CM, Rajman I, Prescott MF, Dole WP. Comparative efficacy and safety of aliskrein and irbesartan in patients with hypertension and metabolic syndrome. J Hum Hypertens 2011; 25: 186-195.
7. Kushiro T, Itakura H, Abo Y, Gotou H, Terao S, Keefe DL. Aliskrein, a novel oral renin inhibitor, provides dose-dependent efficacy and placebo-like tolerability in Japanese patients with hypertension. Hypertens Res 2006; 29: 997-1005.
8. White WB, Bresalier R, Kaplan AP, Palmer BF, Riddell RH, Lesogor A, Chang W, Keefe DL. Safety and tolerability of the direct renin inhibitor aliskiren: a pooled analysis of clinical experience in more than 12000 patients with hypertension. J Clin Hypertens 2010; 12: 765-775.
9. Nussberger J, Wuerzer G, Jensen C, Brunner HR. Angiotensin II suppression in humans by the orally active renin inhibitor aliskiren (SPP100). Comparison with enalapril. Hypertension 2002; 39: e1-e8.
10. Persson F, Lewis JB, Lewis EJ, Rossing P, Hollenberg NK, Parving HH. Impact of aliskiren treatment on urinary aldosterone levels in patients with type 2 diabetes and nephropathy: an AVOID substudy. J Renin Angiotensin Aldosterone Syst 2012; 13: 118-121.
11. Sato A, Saruta T. Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy. J Int Med Res 2001; 29: 13-21.
12. Sato A, Saruta T. Aldosterone breakthrough during angiotensin-converting enzyme inhibitor therapy. Am J Hypertens 2003; 16: 781-788.
13. Yoneda T, Takeda Y, Usukura M, Oda N, Takata H, Yamamoto Y, Karashima S, Yamagishi M. Aldosterone breakthrough during angiotensin II receptor blockade in hypertensive patients with diabetes mellitus. Am J Hypertens 2007; 20: 1329-1333.
14. Naruse M, Tanabe A, Sato A, Takage S, Tsuchiya K, Imaki T, Takano K. Aldosterone breakthrough during angiotensin II receptor antagonist therapy in stroke-prone spontaneously hypertensive rats. Hypertension 2002; 40: 28-33.
15. Sato A, Hayashi K, Naruse M, Saruta T. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 2003; 41: 64-68.
16. Sato A, Hayashi K, Saruta T. Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease. Am J Hypertens 2005; 18: 44-49.
17. Sato A, Saruta T, Funder JW. Combination therapy with aldosterone blockade and renin-angiotensin inhibitors confers organ protection. Hypertens Res 2006; 29: 211-216.
18. Abe M, Okada K, Maruyama N, Matsumoto S, Maruyama T, Fujita T, Matsumoto K, Soma M. Benidipine reduces albuminuria and plasma aldosterone in mild-to-moderate stage chronic kidney disease with albuminuria. Hypertens Res 2011; 34: 268-273.
19. Kondo T, Goto R, Sonoda K, Yasuda T, Ono K, Takaki Y, Yatsuda R, Miyamura N, Araki E. Plasma renin activity and aldosterone concentration are not altered by the novel calcium channel antagonist, azelnidipine, in hypertensive patients. Inter Med 2010; 49: 637-643.
20. Konoshita T, Makino Y, Kimura T, Fujii M, Wakahara S, Arakawa K, Inoki I, Nakamura H, Miyamori I, the Genomic Disease Outcome Consortium (G-DOC) Study Investigators. A new-generation N/L-type calcium channel blocker leads to less activation of the renin-angiotensin system compared with conventional L type calcium channel blocker. J Hypertens 2010; 28: 2156-2160.
21. Van de Wal RMA, Plokker HWM, Lok DJA, Boomsma F, van de Horst FAL, Van Veldhisen DJ, van Gilst WH, Voors AA. Determinants of increased angiotensin II level in severe chronic heart failure patients despite ACE inhibition. Int J Cardiol 2006; 106: 367-372.
22. Bomback AS. The incidence and implications of aldosterone breakthrough. Nat Clin Pract Nephrol 2007; 3: 486-492.
23. Sato A, Suzuki Y, Shibata H, Saruta T. Plasma aldosterone concentrations are not related to the degree of angiotensin-converting enzyme inhibition in essential hypertensive patients. Hypertens Res 2000; 23: 25-31.
24. Borghic C, Boschi S, Ambrosioni E, Melandri G, Branzi A, Magnani B. Evidence of a partial escape of renin-angiotensin-aldosterone blockade in patients with acute myocardial infarction treated with ACE inhibitors. J Clin Pharmacol 1993; 33: 40-45.
25. Rocha R, Chander PN, Zuckerman A, Stier CT Jr. Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats. Hypertension 1999; 33: 232-237.
26. Robles NR, Velasco J, Espinosa J, Mena C, Angulo E, on behalf of the MICREX Group Investigators. Persistent microalbuminuria after treatment with renin-angiotensin axis blockers: causes and results of treatment intensification. J Renin Angiotens Aldo Syst 2011; 12: 333-339.
27. Cerezo C, Ruilope LM, Segura J, Garcia-Donaire JA, de la Cruz JJ, Banegas JR, Waeber B, Rabelink TJ, Messerli FH. Microalbuminuria breakthrough under chronic reninangiotensin- aldosterone system suppression. J Hypertens 2012; 30: 204-209.
28. Shiigai T, Shichiri M. Late escape from the antiproteinuric effect of ACE inhibitors in nondiabetic renal disease. Am J Kidney Dis 2001; 37: 477-483.
29. Feldman DL, Jin L, Xuan H, Contrepas A, Zhou Y, Webb RL, Mueller DN, Feldt S, Cumin F, Maniara W, Persohn E, Schuetz H, Jan Danser AH, Nguyen G. Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2927 rats. Hypertension 2008; 52: 130-136.
30. Fisher NDL, Jan Danser AH, Nussberger J, Dole WP, Hollenberg NK. Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans. Circulation 2008; 117: 3199-3205.
31. Krop M, Garrelds IM, de Bruin RJA, van Gool JMG, Fisher NDL, Hollenberg NK, Jan Danser AH. Aliskiren accumulates in renin secretory granules and binds plasma protein. Hypertension 2008; 52: 1076-1083.
32. Parving HH, Persson F, Lewis JB, Hollenberg NK. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008; 358: 2433-2446.
33. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Kober L, Maqqioni AP, Solomon SD, Swedberg K, Van de Werf F, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, Califf RM, Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349: 1893-1906.
34. ONTARGET InvestigatorsYusuf S, Teo KK, Poque J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547-1559.
35. Parving HH, Brenner BM, McMurray JJV, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Ghadanfar M, Weissbach N, Xiang Z, Armbrecht J, Pfeffer MA. Aliskiren trial in type 2 diabetes using cardio-renal endopoints (ALTITUDE): rationale and study design. Nephrol Dial Transplant 2009; 24: 1663-1671.
36. Pitt B, Zannad F, Remme W, Cody R, Castaigne A, Perez A, Palensky J, Wittes J, for The Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341: 709-717.
37. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M, for The Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309-1321.
38. Zannad F, McMurray JJV, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B, for the EMPHASIS-HF Study Group. Eplrerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011; 364: 11-21.
39. Pitt B, Reichek N, Willenbrock R, Zannad F, Phillips RA, Roniker B, Kleiman J, Krause S, Burns D, Williams GH. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy. The 4E-Left Ventricular Hypertrophy Study. Circulation 2003; 108: 1831-1838.
40. Rossing K, Schjoedt KJ, Smidt UM, Boomsma F, Parving HH. Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy. Diabetes Care 2005; 28: 2106-2112.
41. Schjoedt KJ, Rossing K, Juhl TR, Boomsma F, Tarnow L, Rossing P, Parving HH. Beneficial impact of spironolactone on nephritic range albuminuria in diabetic nephropathy. Kidney Int 2006; 70: 536-542.
42. Bianchi S, Bigazzi R, Campese VM. Antagonists of aldosterone and proteinuria in patients with CKD: An uncontrolled pilot study. Am J Kidney Dis 2005; 46: 45-51.
43. Chrysostomou A, Pedagogos E, MacGregor L, Becker GJ. Double-blind, placebocontrolled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker. Clin J Am Soc Nephrol 2006; 1: 256-262.
44. Epstein M, Williams GH, Weinberger M, Lewin A, Krause S, Mukherjee R, Patni R, Beckerman B. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol 2006; 1: 940-951.